Among these agents, sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors have emerged as a key treatment option not only to provide glycaemic control in diabetes mellitus (DM) but also to offer cardiovascular benefits in HF patients independent of the presence of diabetes status and left ventricular ejection fraction (LVEF), thereby reducing hospitalization rates and cardiovascular mortality [3, 4, 5]. The gene discussed is SLC5A2; the disease is hydrops fetalis.